Literature DB >> 34967764

Association of Brain Injury Biomarkers and Circulatory Shock Following Moderate-Severe Traumatic Brain Injury: A TRACK-TBI Study.

Camilo Toro1, Sonia Jain, Shelly Sun, Nancy Temkin, Jason Barber, Geoffrey Manley, Jordan M Komisarow, Tetsu Ohnuma, Brandon Foreman, Frederick Korley, Michael L James, Daniel Laskowitz, Monica S Vavilala, Adrian Hernandez, Joseph P Mathew, Amy J Markowitz, Vijay Krishnamoorthy.   

Abstract

INTRODUCTION: Early circulatory shock following traumatic brain injury (TBI) is a multifactorial process; however, the impact of brain injury biomarkers on the risk of shock has not been evaluated. We examined the association between neuronal injury biomarker levels and the development of circulatory shock following moderate-severe TBI.
METHODS: In this retrospective cohort study, we examined adults with moderate-severe TBI (Glasgow Coma Scale score <13) enrolled in the TRACK-TBI study, an 18-center prospective TBI cohort study. The exposures were day-1 levels of neuronal injury biomarkers (glial fibrillary acidic protein, ubiquitin C-terminal hydrolase-L1 [UCH-L1], S100 calcium-binding protein B [S100B], neuron-specific enolase), and of an inflammatory biomarker (high-sensitivity C-reactive protein). The primary outcome was the development of circulatory shock, defined as cardiovascular Sequential Organ Failure Assessment Score ≥2 within 72 hours of admission. Association between day-1 biomarker levels and the development of circulatory shock was assessed with regression analysis.
RESULTS: The study included 392 subjects, with a mean age of 40 years; 314 (80%) were male and 165 (42%) developed circulatory shock. Median (interquartile range) day-1 levels of UCH-L1 (994.8 [518.7 to 1988.2] pg/mL vs. 548.1 [280.2 to 1151.9] pg/mL; P<0.0001) and S100B (0.47 μg/mL [0.25 to 0.88] vs. 0.27 [0.16 to 0.46] μg/mL; P<0.0001) were elevated in those who developed early circulatory shock compared with those who did not. In multivariable regression, there were associations between levels of both UCH-L1 (odds ratio, 1.63 [95% confidence interval, 1.25-2.12]; P<0.0005) and S100B (odds ratio, 1.73 [95% confidence interval 1.27-2.36]; P<0.0005) with the development of circulatory shock.
CONCLUSION: Neuronal injury biomarkers may provide the improved mechanistic understanding and possibly early identification of patients at risk for early circulatory shock following moderate-severe TBI.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 34967764      PMCID: PMC9243189          DOI: 10.1097/ANA.0000000000000828

Source DB:  PubMed          Journal:  J Neurosurg Anesthesiol        ISSN: 0898-4921            Impact factor:   3.969


  44 in total

1.  Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results.

Authors:  U Missler; M Wiesmann; G Wittmann; O Magerkurth; H Hagenström
Journal:  Clin Chem       Date:  1999-01       Impact factor: 8.327

2.  Guidelines for the Management of Severe Traumatic Brain Injury, Fourth Edition.

Authors:  Nancy Carney; Annette M Totten; Cindy O'Reilly; Jamie S Ullman; Gregory W J Hawryluk; Michael J Bell; Susan L Bratton; Randall Chesnut; Odette A Harris; Niranjan Kissoon; Andres M Rubiano; Lori Shutter; Robert C Tasker; Monica S Vavilala; Jack Wilberger; David W Wright; Jamshid Ghajar
Journal:  Neurosurgery       Date:  2017-01-01       Impact factor: 4.654

3.  Point-of-Care Platform Blood Biomarker Testing of Glial Fibrillary Acidic Protein versus S100 Calcium-Binding Protein B for Prediction of Traumatic Brain Injuries: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study.

Authors:  David O Okonkwo; Ross C Puffer; Ava M Puccio; Esther L Yuh; John K Yue; Ramon Diaz-Arrastia; Frederick K Korley; Kevin K W Wang; Xiaoying Sun; Sabrina R Taylor; Pratik Mukherjee; Amy J Markowitz; Sonia Jain; Geoffrey T Manley
Journal:  J Neurotrauma       Date:  2020-09-14       Impact factor: 5.269

4.  Validation of the American Spinal Injury Association (ASIA) motor score and the National Acute Spinal Cord Injury Study (NASCIS) motor score.

Authors:  W S El Masry; M Tsubo; S Katoh; Y H El Miligui; A Khan
Journal:  Spine (Phila Pa 1976)       Date:  1996-03-01       Impact factor: 3.468

5.  Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein.

Authors:  Ramon Diaz-Arrastia; Kevin K W Wang; Linda Papa; Marco D Sorani; John K Yue; Ava M Puccio; Paul J McMahon; Tomoo Inoue; Esther L Yuh; Hester F Lingsma; Andrew I R Maas; Alex B Valadka; David O Okonkwo; Geoffrey T Manley
Journal:  J Neurotrauma       Date:  2013-10-09       Impact factor: 5.269

6.  A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults.

Authors:  L E Rosengren; C Wikkelsø; L Hagberg
Journal:  J Neurosci Methods       Date:  1994-03       Impact factor: 2.390

7.  Extracranial complications in patients with acute brain injury: a post-hoc analysis of the SOAP study.

Authors:  Luciana Mascia; Yasser Sakr; Daniela Pasero; Didier Payen; Konrad Reinhart; Jean-Louis Vincent
Journal:  Intensive Care Med       Date:  2008-01-04       Impact factor: 17.440

8.  Secondary peaks of S100B in serum relate to subsequent radiological pathology in traumatic brain injury.

Authors:  Eric P Thelin; David W Nelson; Bo-Michael Bellander
Journal:  Neurocrit Care       Date:  2014-04       Impact factor: 3.210

9.  Increases of Plasma Levels of Glial Fibrillary Acidic Protein, Tau, and Amyloid β up to 90 Days after Traumatic Brain Injury.

Authors:  Tanya Bogoslovsky; David Wilson; Yao Chen; David Hanlon; Jessica Gill; Andreas Jeromin; Linan Song; Carol Moore; Yunhua Gong; Kimbra Kenney; Ramon Diaz-Arrastia
Journal:  J Neurotrauma       Date:  2016-07-08       Impact factor: 5.269

Review 10.  Biomarkers of Traumatic Brain Injury: Temporal Changes in Body Fluids.

Authors:  Harel Adrian; Kvist Mårten; Nuutinen Salla; Välimaa Lasse
Journal:  eNeuro       Date:  2016-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.